Human CD64 (Luc) Jurkat Reporter Cell Development Service
描述（Description）
The Human CD64 (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor human CD64 (Gene ID: 2209), which can use to evaluate ADCP activity of antibodies in the presence of corresponding target cells. When co-cultured with a target cell and relevant antibody, the antibody simultaneously binds the target cell antigen and CD64 receptor on the surface of Human CD64 (Luc) Jurkat Reporter Cell, resulting in receptor clustering, intracellular signaling and NFAT-mediated luminescence.
應(yīng)用說明（Application）
Determination of ADCP activity induced by antibodies
生長(zhǎng)特性（Growth Properties）
Suspension
篩選標(biāo)記（Selection Marker）
Puromycin (5 μg/mL) + Hygromycin (20 μg/mL)
培養(yǎng)基（Culture Medium）
RPMI-1640 + 10% FBS
凍存液（Freeze Medium）
Serum-free cell cryopreservation medium
裝量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存儲(chǔ)（Storage）
Frozen in liquid nitrogen.
支原體檢測(cè)（Mycoplasma Testing）
Negative
無菌檢測(cè)（Sterility Testing）
Negative
使用說明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
背景（Background）
Fcγ receptors (FcγRs), the largest group of FcRs, bind IgG and comprise several subtypes. FcγRI (CD64), a high-affinity receptor that binds monomeric uncomplexed IgG molecules. FcγRI saturation by endogenous circulating IgGs in vivo may attenuate its role in mediating antibody function.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
關(guān)鍵字： CD64報(bào)告細(xì)胞系;CD64細(xì)胞系;CD64細(xì)胞株;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。